Impact Biomedical Inc. announced a reverse stock split at a ratio of 1-for-12.62, effective September 23, 2026, to support its proposed merger with Zoar Limited and regain NYSE American listing compliance. The transaction reduces outstanding shares from approximately 107.8 million to 8.5 million, with fractional shares rounded up. This action follows shareholder authorization in December 2025 for a split between 1-for-12.48 and 1-for-50. Impact Biomedical Inc. discovers and patents technologies for biopharmaceuticals and consumer healthcare.